ANDI Funded Projects
Evaluation of Medical Device Suite for Child Health – Malawi/ Rice University Project:
Developing novel drugs from African traditional medicinal knowledge is a means to improve Public health and support development. Building on the knowledge of a traditional medicine practitioner, Nigeria’s National Institute for Pharmaceutical Research and Development (NIPRD) developed the traditional herbal medicine Niprisan- a novel drug for the treatment of sickle cell anemia, a chronic blood disorder with few effective therapies. ANDI is now investing on that project by supporting the development of a novel and user friendly formulation of NIPRISAN with other drugs used for the management of sickle cell disease (SCD). The commercialization of Niprisan reached a number of commercial milestones, including regulatory approval in Nigeria; securing US-based commercial partner; demonstrating clinical efficacy and safety; awarded orphan drug status by the US Food and Drug Administration; and striking important relationships with domestic and international groups. Despite these successes, the development and commercialization of Niprisan has still not been concluded. A number of reasons, including inconsistent funding, manufacturing and management challenges, have cause developmental and commercialization challenges. NIPRD is considering options for another commercial partner to take the commercialization of the drug forward.
ANDI/WHO Demonstration Project:
ANDI is collaborating with African and Chinese institutions and companies to develop new diagnostic tools for neglected diseases including Schistosomiasis, Echinococcosis, African Sleeping Sickness, malaria (vivax and falciparum), and HIV. The new technology leverages the high throughput biomarker technology developed by China NDI research group. The technology proves to be innovative in addressing the major limitation of the current traditional diagnostic methods such as parasitological or clinical methods that are neither simple nor convenient for population based monitoring and surveillance and has low sensitivity and specificity. ANDI has secured some funding to support this project through a competitive World Health Organization’s, intergovernmental process to support few demonstration projects that has a potential for high impact. This effort has already resulted in two promising novel diagnostics for Schistosomiasis from China and Egypt, and we are now working to develop a technology transfer mechanism to support further evaluation, local production and distribution in Africa through a social venture mechanism. This project is also close to identifying a single diagnostics tool for malaria which will go far in supporting the control and elimination of malaria.
 Levels & Trends in Child Mortality: Report 2015 Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation. Accessed from: http://www.childmortality.org/files_v20/download/IGME%20report%202015%20child%20mortality%20final.pdf
 The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan: BMC Int Health Hum Rights. 2010; 10(Suppl 1): S11. Published online 2010 Dec 13. doi: 10.1186/1472-698X-10-S1-S11